Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

225 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Quality of life in clinical trials for children.
Trama A, Dieci M. Trama A, et al. Among authors: dieci m. Eur J Clin Pharmacol. 2011 May;67 Suppl 1:41-7. doi: 10.1007/s00228-010-0924-0. Epub 2010 Nov 21. Eur J Clin Pharmacol. 2011. PMID: 21104074 Review.
Incidence of non-colorectal/endometrial malignancies in individuals with Lynch syndrome: a retrospective cohort study.
Negro S, Celotto F, Schiavi F, Scarpa M, Mammi I, Rossi S, Dell'Atti L, De Grandis MC, Crivellari G, Fassan M, Agostini M, Spolverato G, Cappello F, D'Angelo E, Milella M, Bencivenga M, Pilati P, Lonardi S, Intini R, Guarneri V, Dieci MV, Morabito A, Barana D, D'Urso A, Iafrate M, Bergamo F, Urso EDL. Negro S, et al. Among authors: dieci mv. EClinicalMedicine. 2025 Nov 3;90:103618. doi: 10.1016/j.eclinm.2025.103618. eCollection 2025 Dec. EClinicalMedicine. 2025. PMID: 41497507 Free PMC article.
Basal-like HR + /HER2- breast cancers show higher tumor-infiltrating lymphocytes and immune signatures with potential therapeutic implications.
Griguolo G, Bottosso M, Paré L, Miglietta F, Generali DG, Musolino A, Spazzapan S, Vernaci GM, Giarratano T, Cappellesso R, Bicciato S, Piacentini F, Tagliafico E, Cagossi K, Tosi A, Schiavi F, Prat A, Dieci MV, Guarneri V. Griguolo G, et al. Among authors: dieci mv. NPJ Breast Cancer. 2025 Dec 24. doi: 10.1038/s41523-025-00886-w. Online ahead of print. NPJ Breast Cancer. 2025. PMID: 41444238 Free article.
PIK3CA mutations and first-line outcomes in endocrine-resistant HR+/HER2- metastatic breast cancer: A multicentric real-world study.
Dieci MV, Vernaci G, Colangelo C, Bria E, Massa D, Di Liso E, Giorgi CA, Giarratano T, Napetti D, Bonomi G, Zanghì F, Bottosso M, Lazzarini E, Santarelli L, Boscolo Bragadin A, Indraccolo S, Guarneri V. Dieci MV, et al. Eur J Cancer. 2025 Dec 19;234:116194. doi: 10.1016/j.ejca.2025.116194. Online ahead of print. Eur J Cancer. 2025. PMID: 41435752 Free article.
Efficacy and safety of systemic therapies following progression on CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer: a systematic review and network meta-analysis.
Buonaiuto R, Fordellone M, Caltavituro A, Cataldo ML, Criscitiello C, Dieci MV, Lambertini M, Botticelli A, Giuliano M, Giordano A, Mangiacotti F, Grieco A, Longobardi A, Caputo R, Pagliuca M, Vernieri C, Malorni L, Gerratana L, Arpino G, Chiodini P, De Laurentiis M, De Angelis C. Buonaiuto R, et al. Among authors: dieci mv. EClinicalMedicine. 2025 Sep 30;89:103535. doi: 10.1016/j.eclinm.2025.103535. eCollection 2025 Nov. EClinicalMedicine. 2025. PMID: 41079023 Free PMC article.
225 results